Cerner working with Elligo, Frenome on multiomics for early cancer detection

With real-world data from its Learning Health Network, Cerner hopes to advance oncology innovation and expand access to clinical trials.

Cerner this week announced that it is collaborating with Elligo Health Research and Freenome for a clinical trial project that seeks to advance early cancer detection via insights derived from Cerner's Learning Health Network.

WHY IT MATTERS
The three companies will be harness real-world data from the network's participating health system and use Freenome's "multiomics" technology for the Sanderson Study, an forthcoming clinical trial designed to detect multiple types of cancer.

Freenome’s platform uses machine learning models to analyze tumor and non-tumor signals, with the goal of detecting cancer in its earliest, most treatable stages with a single blood draw. The aim is to innovate a more patient-centric approach to multi-cancer detection, reducing diagnostic complexity and optimizing processes for clinical efficiency.